Raffles Medical Group Ltd
Raffles Medical Group Ltd (RAFLF) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for Raffles Medical Group Ltd (RAFLF), featuring income statements, balance sheets, and cash flow data.
Raffles Medical Group Ltd (RAFLF) Income Statement & Financial Overview
Explore comprehensive income reports for Raffles Medical Group Ltd RAFLF, broken down by year and quarter.
| Metric | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $182.84M | $182.84M | $127.75M | $123.32M |
| Cost of Revenue | $100.71M | $100.71M | $52.25M | $50.44M |
| Gross Profit | $82.14M | $82.14M | $75.50M | $72.88M |
| Gross Profit Ratio | $0.45 | $0.45 | $0.59 | $0.59 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $41.77M | $41.77M | $53.12M | $51.27M |
| Operating Expenses | $61.50M | $61.50M | $60.69M | $58.58M |
| Total Costs & Expenses | $162.21M | $162.21M | $112.94M | $109.03M |
| Interest Income | $5.30M | $1.07M | $3.96M | $703689.00 |
| Interest Expense | $3.16M | $0.00 | $2.54M | $0.00 |
| Depreciation & Amortization | $9.36M | $9.36M | $2.58M | $2.49M |
| EBITDA | $30.003M | $30.003M | $14.52M | $14.02M |
| EBITDA Ratio | $0.16 | $0.16 | $0.11 | $0.11 |
| Operating Income | $20.64M | $20.64M | $11.94M | $11.53M |
| Operating Income Ratio | $0.11 | $0.11 | $0.09 | $0.09 |
| Other Income/Expenses (Net) | $1.07M | $1.07M | $3.60M | $3.47M |
| Income Before Tax | $21.71M | $21.71M | $15.54M | $15.000M |
| Income Before Tax Ratio | $0.12 | $0.12 | $0.12 | $0.12 |
| Income Tax Expense | $6.24M | $6.24M | $3.92M | $3.78M |
| Net Income | $15.32M | $15.32M | $11.48M | $11.08M |
| Net Income Ratio | $0.08 | $0.08 | $0.09 | $0.09 |
| EPS | $0.008 | $0.008 | $0.006 | $0.006 |
| Diluted EPS | $0.008 | $0.008 | $0.006 | $0.006 |
| Weighted Avg Shares Outstanding | $1.89B | $1.89B | $1.87B | $1.87B |
| Weighted Avg Shares Outstanding (Diluted) | $1.89B | $1.89B | $1.87B | $1.87B |
The company's financials show resilient growth, with revenue advancing from $123.32M in Q3 2023 to $182.84M in Q2 2024. Gross profit remained healthy with margins at 45% in Q2 2024 compared to 59% in Q3 2023. Operating income hit $20.64M last quarter, sustaining a consistent 11% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $30.003M. Net income rose to $15.32M, while earnings per share reached $0.008. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan